Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Exact Sciences Corp. (EXAS)
NASDAQ:EXAS
Holding EXAS?
Track your performance easily
EXAS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$40.62 - $79.62
Previous Close$59.4
Volume3.27M
Average Volume (3M)2.41M
Market Cap
$10.38B
Enterprise Value$12.12B
Total Cash (Recent Filing)$1.02B
Total Debt (Recent Filing)$2.76B
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Feb 25, 2025EPS Estimate
-$0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding185,076,293
10 Day Avg. Volume1,737,755
30 Day Avg. Volume2,411,959
Standard Deviation0.16
R-Squared0.17
Alpha-0.00772
Financial Highlights & Ratios
Price to Book (P/B)3.42
Price to Sales (P/S)3.86
Price to Cash Flow (P/CF)18.70
P/FCF Ratio33.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.50
Enterprise Value/Gross Profit6.57
Enterprise Value/Ebitda412.93
Forecast
1Y Price Target
$71.53Price Target Upside20.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
Exact Sciences News
Bulls Say, Bears Say
Bulls Say
Market PerformanceShares of EXAS are up ~10% following news that the company obtained a price of ~$592/test for Cologuard Plus, or a 16% price increase compared to its first generation Cologuard test.
Pricing StrategyThe resolution of uncertainty regarding the price increase for Cologuard Plus helps to reduce risk for the stock.
Revenue GrowthThe higher Cologuard Plus pricing is expected to contribute significantly to revenue growth and improve gross margins.
Bears Say
Competitive PressureEXAS' blood test's sensitivity performance is inferior to stool-based tests like Cologuard Plus and ColoSense.
Financial PerformanceThe company's third-quarter results fell short of expectations, leading to a reduction in guidance for both Cologuard and Oncotype businesses.
Operational ChallengesCommercial and sales representative execution issues have been identified as key challenges, particularly during the critical ramp period.
---
Ownership Overview
1.02% Insiders
43.37% Mutual Funds
35.00% Other Institutional Investors
5.40% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EXAS FAQ
What was Exact Sciences Corp.’s price range in the past 12 months?
Exact Sciences Corp. lowest stock price was $40.62 and its highest was $79.62 in the past 12 months.
What is Exact Sciences Corp.’s market cap?
Currently, no data Available
When is Exact Sciences Corp.’s upcoming earnings report date?
Exact Sciences Corp.’s upcoming earnings report date is Feb 25, 2025 which is in 66 days.
How were Exact Sciences Corp.’s earnings last quarter?
Exact Sciences Corp. released its earnings results on Nov 05, 2024. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.196 by -$0.014.
Is Exact Sciences Corp. overvalued?
According to Wall Street analysts Exact Sciences Corp.’s price is currently Undervalued.
Does Exact Sciences Corp. pay dividends?
Exact Sciences Corp. does not currently pay dividends.
What is Exact Sciences Corp.’s EPS estimate?
Exact Sciences Corp.’s EPS estimate is -$0.33.
How many shares outstanding does Exact Sciences Corp. have?
Exact Sciences Corp. has 185,076,300 shares outstanding.
What happened to Exact Sciences Corp.’s price movement after its last earnings report?
Exact Sciences Corp. reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.196. Following the earnings report the stock price went down -23.479%.
Which hedge fund is a major shareholder of Exact Sciences Corp.?
Among the largest hedge funds holding Exact Sciences Corp.’s share is PRIMECAP Management Co. It holds Exact Sciences Corp.’s shares valued at 34M.
---
Exact Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$71.53 (20.42% Upside)
$71.53 (20.42% Upside)
Blogger Sentiment
Bullish
EXAS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 267.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.73%
12-Months-Change
Fundamentals
Return on Equity
-6.76%
Trailing 12-Months
Asset Growth
5.10%
Trailing 12-Months
Company Description
Exact Sciences Corp.
Founded in 1995, Wisconsin-based Exact Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer.
---
EXAS Company Deck
---
EXAS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth, profitability, and operational achievements, including the FDA approval of Cologuard Plus. However, execution challenges, particularly in Cologuard order growth, hurricane impacts, and transitional issues in Precision Oncology, weighed on the company's outlook for the rest of the year.Read More>---
EXAS Revenue Breakdown
74.59% Screening
25.17% Precision Oncology
0.24% COVID-19 Testing
---
EXAS Stock 12 Month Forecast
Average Price Target
$71.53
▲(20.42% Upside)
Technical Analysis
Best Analysts Covering EXAS
1 Year
1 Year Success Rate
15/21 ratings generated profit
1 Year Average Return
+33.14%
reiterated a buy rating 3 months ago
Copying Doug Schenkel's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +33.14% per trade.
---